Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 6.16 on March 18, 2026. This significant decline reflects a challenging year for the company, with a staggering 69.92% drop in its stock price over the past year, contrasting sharply with the S&P 500's performance of 17.99% during the same period. The company's market capitalization stands at USD 1,650 million, and it currently has a price-to-earnings (P/E) ratio of 3.00, indicating a low valuation compared to its earnings. Despite a modest dividend yield of 0.94%, Organon has faced difficulties, including a negative operating profit margin of -3.44% and a concerning inventory turnover ratio of just 2 times. Financial metrics reveal a decline in net profit, which fell by 35.56% to USD 142.47 million in the latest quarter, alongside a 6.27% increase in raw material costs year-over-year. With a return on equity of 0.00% and a price-to-book ratio of 0.00, the company is navigating a challenging landscape, marked by below-par performance both in the short and long term.